A Pathway to New Antibiotics

A conversation with Dr. Helen Boucher

A Pathway to New Antibiotics
Dr. Helen Boucher © The Pew Charitable Trusts

Dr. Boucher has urged support for the need to develop a limited-population antibacterial drug (LPAD) approval pathway at congressional briefings.

Dr. Helen Boucher directs the Infectious Diseases Fellowship Program and the Ventricular Assist Device and Cardiac Transplant Infectious Diseases Program at Tufts Medical Center (TMC), and is an associate professor at Tufts University School of Medicine. She is a voting member on the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria and has spoken at length about the threat of antibiotic resistance to modern medicine. Dr. Boucher is also a member of the board of directors of the Infectious Diseases Society of America.

Dr. Boucher has urged support for the need to develop a limited-population antibacterial drug (LPAD) approval pathway at congressional briefings. LPAD would enable the approval of new antibiotics that target serious or life-threatening drug-resistant infections in patients who have few or no suitable treatment options.

Q: Why do you support the LPAD approval pathway?

A: LPAD offers a chance to get patients the medicines they need now. I support anything that is safe and effective to help expedite the path forward for new treatment options. LPAD is one of many steps in the right direction, but certainly an important one.

Q: What do you say to critics who say LPAD would lower or compromise patient safety standards?

A: LPAD does not change the standard for safety or efficacy of drug approvals. LPAD simply allows for smaller clinical development programs that are focused on the limited, high-risk populations that would use the new antibiotics. With approval of these types of drugs comes the need to use them well. Additionally, antibiotic monitoring and stewardship are important components of LPAD. They would make sure these drugs are used in the way they are intended.

Q: What difference would LPAD make in your practice? What would be the real-world implications of an LPAD pathway?

A: I would likely have something to offer patients whom I currently have to send to hospice care, or tell I’ve run out of options. LPAD would allow for development of a broad array of antibiotics, including oral drugs (this is significant since IVs sometimes carry risk of health care-acquired infections).

Q: Do you have any closing thoughts with respect to LPAD?

A: There are several steps necessary to fight antibiotic resistance. New therapeutics are a key part of the solution. What we need is a way forward that is sustainable for future generations, but it won’t be a quick fix. We need to find a way to foster a robust drug development pipeline.

Antibiotics pharmacy
Antibiotics pharmacy
Article

Addressing the Regulatory Hurdles Facing Antibiotic Innovation

Quick View
Article

Although the threat of antibiotic resistance is growing, it can be challenging to get regulatory approval for antibiotics that treat highly resistant bacterial infections. Only a small number of patients contracting such infections meet the requirements to participate in traditional large clinical trials. As a result, researchers have difficulty identifying patients and enrolling them in clinical trials to study treatments for some of the most serious bacterial infections.

CARB
CARB
Article

Briefing: Developing an Approval Pathway for Limited-Population Antibacterial Drugs

Quick View
Article

The Pew Charitable Trusts, the Infectious Diseases Society of America (IDSA), and Trust for America’s Health co-sponsored a July 28 briefing with a panel of antibacterial drug experts and stakeholders to discuss the development of a limited-population antibacterial drug (LPAD) approval pathway. Bipartisan legislation has been approved by the House of Representatives and introduced in the Senate: the Promise for Antibiotics and Therapeutics for Health (PATH) Act, S. 185.

Antibiotics
Antibiotics
Article

LPAD: A Regulatory Pathway to Develop Antibiotics and Fight Drug-Resistant Infections

Quick View
Article

The Antibiotic Development to Advance Patient Treatment (ADAPT) Act, originally introduced in 2013, was recently included as part of the 21st Century Cures Act, the wide-ranging health care bill approved by the House Energy and Commerce Committee on May 21. ADAPT, along with companion legislation in the Senate (the Promise for Antibiotics and Therapeutics for Health, or PATH, Act) would require the Food and Drug Administration to establish a new approval process known as the Limited-Population Antibacterial Drug pathway, or LPAD.